On November 11, GeneDx Holdings rose 5.51% in Regular Trading, trading near $58.25 per share, with turnover of $6.7877 million.
The clearest catalyst in recent public disclosures was post-earnings analyst support: Piper Sandler maintained a Buy rating with a $95 price target, while BTIG also kept its Buy rating, though it lowered its target to $85 from $90.
That followed GeneDx Holdings reporting quarterly adjusted EPS of $0.28, above the $0.07 consensus estimate, on revenue of $123.1 million versus expectations of $122.9 million. Revenue guidance for Q4 was $135 million, below the $142.6 million consensus, while the company reiterated full-year revenue guidance of $475 million to $490 million. The mixed print helps explain why rating support, rather than the earnings release alone, appears most relevant to the latest rebound.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments